Suppliers / Jiangsu Xidi Pharmaceuticals

Jiangsu Xidi Pharmaceuticals

China Updated 9 July 2026

Jiangsu Xidi Pharmaceuticals is an API manufacturer based in China. It holds 2 active US drug master files and one valid CEP across a filed portfolio of 7 molecules.

2
active US DMFs
1
valid CEPs
2
registered plants 1 with an FDA FEI number
10
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026.

Registered plants

Site FDA FEI
Qidong, China Not on file
China, China 3013431774

What they file, and where

Molecule Regulators Docs
Nilotinib SFDA (Saudi Arabia) 3
Abiraterone SFDA (Saudi Arabia) 1
Cabazitaxel US FDA 1
Carfilzomib US FDA 1
Irinotecan EDQM 1
Lapatinib Ditosylate SFDA (Saudi Arabia) 1
Lenvatinib SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Cabazitaxel API Carfilzomib API Irinotecan API Lenvatinib API Nilotinib API Abiraterone API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 10 None

Comparing suppliers?

Choose your molecules and target markets. Jiangsu Xidi Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability